« Back
Home /
Rebastinib

Rebastinib

Item no.	HY-13024-5mg
Manufacturer	MedChem Express
CASRN	1020172-07-9
Amount	5 mg
Quantity options	10mM/1mL 10 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.91
Formula	C30H28FN7O3
Citations	[1]Chan WW, et al. Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036. Cancer Cell. 2011, 19(4), 556-568.
Smiles	CC(C)(C)C1=NN(C(NC(NC2=C(F)C=C(OC3=CC(C(NC)=O)=NC=C3)C=C2)=O)=C1)C4=CC=C5C(C=CC=N5)=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	DCC-2036
Available
Product Description	Rebastinib (DCC-2036) is an orally active, non-ATP-competitive Bcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. Rebastinib also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit.
StorageTemperature	-20°C, 3 years; 4°C, 2 years (Powder)
Shipping	Room Temperature
Manufacturers Applications	Cancer-Kinase/protease
MolecularWeight	553.59
Clinical_Information	Phase 2
Manufacturers Research Area	Cancer
Solubility	DMSO : 50 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturers Target	Apoptosis; Bcr-Abl; FLT3; Src
Pathway	Apoptosis; Protein Tyrosine Kinase/RTK

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13024-5mg-safety-datasheet.pdf